Safety and efficacy of DOACs for non-cirrhotic splanchnic vein thrombosis: a single centre retrospective analysis.

BACKGROUND

In recent years, increasing evidence has emerged regarding the use of direct oral anticoagulants (DOACs) for the treatment of splanchnic vein thrombosis (SVT) in non-cirrhotic patients. However, available data are predominantly retrospective, derived from small and heterogeneous cohorts; consequently, the use of DOACs for this indication remains off-label.

METHODS

To further evaluate the safety and efficacy of DOACs in this setting, 21 consecutive patients with acute non-cirrhotic SVT were enrolled and treated with DOACs for a minimum of 6 months.

RESULTS

No cases of SVT progression, recurrence, or major bleeding were observed during follow-up. One patient experienced a minor bleeding event.

CONCLUSIONS

These findings are consistent with previous reports indicating a favorable safety profile of DOACs, with a low risk of bleeding. However, conclusions regarding efficacy remain uncertain, precluding definitive inferences on their effectiveness in non-cirrhotic SVT. Larger, well-designed prospective studies are required to clarify the true efficacy of DOACs in this clinical setting.